S. Blach et al., “Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study,” Lancet Gastroenterol. Hepatol., vol. 2, no. 3, pp. 161–176, Mar. 2017.
 World Health Organization, World Health Organization, and Replacement of (work) World Health Organization., Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. .
 J. V. Lazarus et al., “The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations,” Seminars in Liver Disease. 2018.
 S. A. Glynn et al., “Dynamics of viremia in early hepatitis C virus infection,” Transfusion, 2005.
 V. Sypsa et al., “Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients,” Am. J. Kidney Dis., 2005.
 M. Miedouge, K. Saune, N. Kamar, M. Rieu, L. Rostaing, and J. Izopet, “Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients,” J. Clin. Virol., vol. 48, no. 1, pp. 18–21, May 2010.
 S. Chevaliez, A. Soulier, L. Poiteau, M. Bouvier-Alias, and J. M. Pawlotsky, “Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C,” J. Clin. Virol., vol. 61, no. 1, pp. 145–148, 2014.
 C. A. Rongey, F. Kanwal, T. Hoang, A. L. Gifford, and S. M. Asch, “Viral RNA Testing in Hepatitis C Antibody-Positive Veterans,” Am. J. Prev. Med., vol. 36, no. 3, pp. 235–238, 2009.
 F. M. J. Lamoury et al., “Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse,” J. Clin. Virol., vol. 92, pp. 32–38, Jul. 2017.
 J. M. Freiman et al., “Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: A systematic review and meta-analysis,” Ann. Intern. Med., vol. 165, no. 5, pp. 345–355, Sep. 2016.
 I. Mederacke et al., “Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease,” Nephrol. Dial. Transplant., vol. 26, no. 8, pp. 2648–2656, 2011.
 M. Jadoul et al., “Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients,” Kidney Int., vol. 95, no. 4, pp. 939–947, 2019.
 P. K. T. Li et al., “2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report,” Kidney Int. Reports, vol. 0, no. May, May 2020.
 I. Mederacke et al., “HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis,” J. Clin. Virol., vol. 53, no. 2, pp. 110–115, Feb. 2012.
 G. Li Cavoli et al., “Hepatitis C Virus Core Antigen Test in Monitoring of Dialysis Patients,” Hepat. Res. Treat., vol. 2012, pp. 1–4, 2012.
 P. Jülicher and C. Galli, “Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting,” J. Med. Econ., vol. 21, no. 1, pp. 1–10, 2018.
 R. Wasitthankasem et al., “HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: Implications for improved diagnostic option in an era of affordable DAAs,” PeerJ, vol. 2017, no. 11, 2017.
 A. Chakravarti, M. S. Chauhan, G. Dogra, and S. Banerjee, “Hepatitis C virus core antigen assay: Can we think beyond convention in resource limited settings?,” Brazilian J. Infect. Dis., vol. 17, no. 3, pp. 369–374, May 2013.
 R. Alonso, F. Pérez-García, P. López-Roa, L. Alcalá, P. Rodeño, and E. Bouza, “HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia,” Enferm. Infecc. Microbiol. Clin., vol. 36, no. 3, pp. 175–178, 2018.
 L. T. Nguyen et al., “Hepatitis C virus core mutations associated with false-negative serological results for genotype 3a core antigen,” J. Clin. Microbiol., vol. 53, no. 8, pp. 2697–2700, Aug. 2015.
 A. R. Garbuglia et al., “HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes,” BMC Infect. Dis., vol. 14, no. 1, Apr. 2014.
 J. E. Trevizoli et al., “Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients,” Clin. J. Am. Soc. Nephrol., 2008.
 A. Goel, D. S. Bhadauria, and R. Aggarwal, “Hepatitis C virus infection and chronic renal disease: A review,” Indian J. Gastroenterol., vol. 37, no. 6, pp. 492–503, 2018.
 H. L. Tillmann, “Hepatitis C virus core antigen testing: Role in diagnosis, disease monitoring and treatment,” World J. Gastroenterol., 2014.
 C. Galli, P. Julicher, and M. Plebani, “HCV core antigen comes of age: A new opportunity for the diagnosis of hepatitis C virus infection,” Clin. Chem. Lab. Med., vol. 56, no. 6, pp. 880–888, 2018.
 E. Hadziyannis, M. Minopetrou, A. Georgiou, F. Spanou, and J. Koskinas, “Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay,” Ann. Gastroenterol., 2013.
 H. S. Wong and B. L. Goh, “24th Report of the Malaysian Dialysis & Transplant 2016,” 2018.
 A. Fifa Rahman Chee Yoke Ling Shangeetha Thirumayni Marcela Fogaça Vieira Sergey Kondratyuk Rosmawati Mohamed Jean-Michel Piedagnel Graphic Designer Goh Yuen Lu, “AT THE EDGE OF A MIRACLE THE HEPATITIS C VIRUS (HCV) EPIDEMIC IN MALAYSIA,” 2017.
 S. Jasuja et al., “Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital,” Indian J. Nephrol., 2009.